{
    "title": "110_hr4200",
    "content": "SECTION 1. TAX CREDIT FOR MEDICAL RESEARCH RELATED TO DEVELOPING \n              QUALIFIED INFECTIOUS DISEASE PRODUCTS.\n\n    (a) In General.--Subpart D of part IV of subchapter A of chapter 1 \nof the Internal Revenue Code of 1986 (relating to business-related \ncredits) is amended by adding at the end the following new section:\n\n``SEC. 45O. CREDIT FOR MEDICAL RESEARCH RELATED TO DEVELOPING QUALIFIED \n              INFECTIOUS DISEASE PRODUCTS.\n\n    ``(a) General Rule.--For purposes of section 38, the infectious \ndisease research credit determined under this section for the taxable \nyear is an amount equal to 50 percent of the qualified infectious \ndisease research expenses for the taxable year.\n    ``(b) Qualified Infectious Disease Research Expenses.--For purposes \nof this section--\n            ``(1) Qualified infectious disease research expenses.--\n        Except as otherwise provided in this subsection, the term \n        `qualified infectious disease research expenses' means the \n        amounts which are paid or incurred by the taxpayer during the \n        taxable year with respect to any research and development of \n        any qualified infectious disease product which would be \n        described in subsection (b) of section 41 if such subsection \n        were applied with the modifications set forth in paragraph (2).\n            ``(2) Modifications; increased incentive for contract \n        research payments.--For purposes of paragraph (1), subsection \n        (b) of section 41 shall be applied--\n                    ``(A) by substituting `qualified infectious disease \n                research' for `qualified research' each place it \n                appears in paragraphs (2) and (3) of such subsection, \n                and\n                    ``(B) by substituting `100 percent' for `65 \n                percent' in paragraph (3)(A) of such subsection.\n            ``(3) Exclusion for amounts funded by grants, etc.--The \n        term `qualified infectious disease research expenses' shall not \n        include any amount to the extent such amount is funded by any \n        grant, contract, or otherwise by another person (or any \n        governmental entity).\n            ``(4) Qualified infectious disease research.--The term \n        `qualified infectious disease research' means qualified \n        research (as defined in section 41(d)) which relates to the \n        development of a qualified infectious disease product, except \n        that qualified infectious disease research shall include \n        expenses related to re-formulating existing qualified \n        infectious disease products.\n            ``(5) Qualified infectious disease product.--\n                    ``(A) In general.--The term `qualified infectious \n                disease product' means any antibiotic drug, antiviral, \n                diagnostic test, biological product, or vaccine that is \n                developed for the purpose of treating, detecting, \n                preventing, or identifying a qualifying pathogen.\n                    ``(B) Qualifying antibiotic drug and antiviral \n                formulations.--To qualify as a qualified infectious \n                disease product under subparagraph (A), any antibiotic \n                drug or antiviral shall be in a formulation for which \n                the Secretary of Health and Human Services, after \n                consulting with infectious diseases clinicians and \n                appropriate professional associations, has determined \n                there is a significant medical need.\n            ``(6) Other definitions.--\n                    ``(A) Antibiotic drug.--The term `antibiotic drug' \n                has the meaning given to that term in section 201 of \n                the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n                321).\n                    ``(B) Antiviral.--The term `antiviral' means a drug \n                or biological product intended for human use that \n                impedes the reproduction of a virus.\n                    ``(C) Biological product.--The term `biological \n                product' has the meaning given to that term in section \n                351 of the Public Health Service Act (42 U.S.C. 262).\n                    ``(D) Device.--The term `device' has the meaning \n                given to that term in section 201 of the Federal Food, \n                Drug, and Cosmetic Act (21 U.S.C. 321).\n                    ``(E) Diagnostic test.--The term `diagnostic test' \n                means a device or product used to detect the presence, \n                concentration, or characteristics of an infectious \n                human disease.\n                    ``(F) Drug.--The term `drug' has the meaning given \n                to that term in section 201 of the Federal Food, Drug, \n                and Cosmetic Act (21 U.S.C. 321).\n                    ``(G) Qualifying pathogen.--The term `qualifying \n                pathogen' means--\n                            ``(i) methicillin-resistant staphylococcus \n                        aureus,\n                            ``(ii) life-threatening gram negative \n                        bacteria, such as Escherichia coli (E. coli), \n                        Acinetobacter, Klebsiella species, and \n                        Pseudomonas aeruginosa,\n                            ``(iii) extensively drug resistant \n                        tuberculosis (XDR-TB), or\n                            ``(iv) any other infectious pathogen \n                        identified for purposes of this section by the \n                        Secretary of Health and Human Services, in \n                        concurrence with infectious disease clinicians \n                        and appropriate professional associations, as a \n                        significant threat to public health because of \n                        drug resistance or other factors (or likely to \n                        become such a threat).\n                    ``(H) Vaccine.--The term `vaccine' means a vaccine \n                intended for human use.\n    ``(c) Coordination With Credit for Increasing Research \nExpenditures.--\n            ``(1) In general.--Except as provided in paragraph (2), any \n        qualified infectious disease research expenses for a taxable \n        year to which an election under this section applies shall not \n        be taken into account for purposes of determining the credit \n        allowable under section 41 for such taxable year.\n            ``(2) Expenses included in determining base period research \n        expenses.--Any qualified infectious disease research expenses \n        for any taxable year which are qualified research expenses \n        (within the meaning of section 41(b)) shall be taken into \n        account in determining base period research expenses for \n        purposes of applying section 41 to subsequent taxable years.\n    ``(d) Special Rules.--\n            ``(1) Certain rules made applicable.--Rules similar to the \n        rules of paragraphs (1) and (2) of section 41(f) shall apply \n        for purposes of this section.\n            ``(2) Coordination with credit for clinical testing \n        expenses for certain drugs for rare diseases.--Any qualified \n        infectious disease research expenses for a taxable year to \n        which an election under this section applies shall not be taken \n        into account for purposes of determining the credit allowable \n        under section 45C for such taxable year.\n            ``(3) Election.--This section shall apply to any taxpayer \n        for any taxable year only if such taxpayer elects (at such time \n        and in such manner as the Secretary may by regulations \n        prescribe) to have this section apply for such taxable year.\n    ``(e) Termination.--This section shall not apply to taxable years \nbeginning after December 31, 2012.''.\n    (b) Inclusion in General Business Credit.--Section 38(b) of the \nInternal Revenue Code of 1986 is amended by striking ``plus'' at the \nend of paragraph (30), by striking the period at the end of paragraph \n(31) and inserting ``, plus'', and by adding at the end the following \nnew paragraph:\n            ``(32) the infectious disease research credit determined \n        under section 45O.''.\n    (c) Denial of Double Benefit.--Section 280C of the Internal Revenue \nCode of 1986 (relating to certain expenses for which credits are \nallowable) is amended by adding at the end the following new \nsubsection:\n    ``(f) Credit for Qualified Infectious Disease Research Expenses.--\n            ``(1) In general.--No deduction shall be allowed for that \n        portion of the qualified infectious disease research expenses \n        (as defined in section 45O(b)) otherwise allowable as a \n        deduction for the taxable year which is equal to the amount of \n        the credit determined for such taxable year under section \n        45O(a).\n            ``(2) Certain rules to apply.--Rules similar to the rules \n        of paragraphs (2), (3), and (4) of subsection (c) shall apply \n        for purposes of this subsection.''.\n    (d) Deduction for Unused Portion of Credit.--Section 196(c) of the \nInternal Revenue Code of 1986 (defining qualified business credits) is \namended by striking ``and'' at the end of paragraph (12), by striking \nthe period at the end of paragraph (13) and inserting ``, and'', and by \nadding at the end the following new paragraph:\n            ``(14) the infectious disease research credit determined \n        under section 45O(a) (other than such credit determined under \n        the rules of section 280C(e)(2)).''.\n    (e) Technical Amendment.--The table of sections for subpart D of \npart IV of subchapter A of chapter 1 of the Internal Revenue Code of \n1986 is amended by adding at the end the following new item:\n\n``Sec. 45O. Credit for medical research related to developing qualified \n                            infectious disease products.''.\n    (f) Effective Date.--The amendments made by this section shall \napply to taxable years beginning after December 31, 2007."
}